ELVN
Enliven Therapeutics, Inc.
Biotechnology · Healthcare · United States
44.25
close · 2026-10-30
value
98
cheaper than peers98
quality
95
stronger fundamentals95
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -2.1% | 96 |
| cash flow yield, 3 years ago | -1.0% | 95 |
| cash flow yield, latest year | -2.2% | 94 |
| cash flow yield, 2 years ago | -1.9% | 90 |
| earnings yield, latest year | -4.1% | 90 |
| cash flow yield, 1 year ago | -2.3% | 89 |
| earnings yield, 2 years ago | -4.5% | 89 |
| earnings yield, 1 year ago | -4.3% | 87 |
| price to book | 3.62× | 39 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.1% | 96 |
| return on equity | -26.6% | 91 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | -$46.1M |
| employees | 61 |
| first trade | 2020-03-12 |
| next earnings | not reported |
| fundamentals updated | 2026-07-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.83 | -1.89 | -2.01 | -0.92 |
| free cash flow | -$70.5M | -$73.2M | -$61.4M | -$32.7M |
| net income | -$103.7M | -$89.0M | -$71.6M | -$37.7M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | $0 | $873,000 | $0 | not reported |